[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.175.236. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
July 6, 1979

TamoxifenUse in Treatment of Metastatic Breast Cancer Refractory to Combination Chemotherapy

Author Affiliations

From the Departments of Medicine (Drs Buzdar, Hortobagyi, Wiseman, and Blumenschein) and Developmental Therapeutics (Drs Legha and Benjamin), University of Texas System Cancer Center, M. D. Anderson Hospital, Houston. Dr Legha is a junior faculty clinical fellow of the American Cancer Society.

JAMA. 1979;242(1):49-52. doi:10.1001/jama.1979.03300010033023
Abstract

Tamoxifen citrate (Nolvadex [Great Britain]; no comparable US product) is a recently developed antiestrogen with significant activity against metastatic breast cancer in postmenopausal women. We investigated its usefulness in breast cancer patients after conventional endocrine therapy and combination chemotherapy had failed. Of the 50 evaluable patients, four (8%) achieved a complete remission, 14 (28%) achieved a partial remission, and ten showed a less than partial response or stabilization of their disease. Median duration of response was eight months, and the survival of responders was significantly prolonged compared to that of the nonresponders. Side effects of the treatment were mild. These results demonstrate that tamoxifen offers the best choice of therapy for patients with metastatic breast cancer after conventional endocrine therapy and combination chemotherapy have failed.

(JAMA 242:49-52, 1979)

×